雙語 | 牟平站：石藥集團煙臺生物醫(yī)藥高科技產(chǎn)業(yè)園項目

　　牟平站 |  “石藥集團煙臺生物醫(yī)藥高科技產(chǎn)業(yè)園”項目：集創(chuàng)新藥物研發(fā)、生產(chǎn)和銷售于一體

　　Yantai Bio-medicine Hi-tech Industrial Park of CSPC in Muping: An Integration of R&D, Production and Sales of New Drugs

　　該項目總投資30億元，占地500畝，是石藥集團在山東唯一的集創(chuàng)新藥物研發(fā)、生產(chǎn)和銷售于一體的高科技生物醫(yī)藥項目。主要有三個特點：

　　The project has a total investment of 3 billion RMB, occupying 500 acres. As the only hi-tech bio-medicine project that integrates R&D, production as well as sales of new drugs in Shandong Province, it owns three dominating features.

　　一是發(fā)展勢頭猛。石藥集團百克(山東)生物制藥有限公司于2010年落戶牟平，2013年底一期建成投產(chǎn)。投產(chǎn)初期年銷售收入1000萬元、納稅不足200萬元，到2016年銷售收入首次突破1億元、納稅突破1000萬元，2022年銷售收入超過25億元、納稅達(dá)到2.3億元，7年增長了25倍。2023年1月納稅4300萬元，同比增長26%，預(yù)計全年納稅2.5億元。

　　The first feature is its dashing momentum for development. CSPC Baike (Shandong) Bio-Pharmaceutical Co., Ltd. headquartered itself in Muping in 2010 and accomplished its first-phase project in 2013. At first, its annual sales revenue was about 10 million RMB with only 2 million taxation. While by the time of 2016, the number reached 100 million RMB for the first time with over 10 million RMB taxation. In 2022, the annual sales revenue exceeded 2.5 billion RMB with taxation of 230 million RMB 25 times within seven years. In January 2023, the company payed taxes of 43 million RMB, a 26% year-on-year increase. A 250-million tax is expected for the entire 2023.

　　二是科技含量高。主打產(chǎn)品“津優(yōu)力”，是國家一類新藥，列入國家重大新藥創(chuàng)制專項，在非髓性惡性腫瘤治療方面具有顯著療效，2017年獲得中國國家專利金獎，2021年獲國家科技進步二等獎。

　　The second feature is the high technology applied to its products, featuring Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) for Injection. It is a new state first-class drug and has been admitted by China's Significant New Drug Development Project. The drug delivers outstanding treatment effects for Non-myeloid malignancies, thus winning the gold medal of China Intellectual Property Award and second prize of the State Preeminent Science and Technology Award.

　　三是成長潛力足。2019年，公司瞄準(zhǔn)國際化發(fā)展目標(biāo)，啟動產(chǎn)業(yè)園二期建設(shè)，目前，津優(yōu)力300萬只擴產(chǎn)項目順利達(dá)產(chǎn)，JMT103和TG103兩個國家一類新藥即將上市投產(chǎn)，達(dá)產(chǎn)后預(yù)計增加產(chǎn)值20億元、稅收2億元。隨著研發(fā)投入超過20億元的7個國家一類新藥陸續(xù)落戶上市，該項目將打造成為石藥集團全國最大的生物醫(yī)藥產(chǎn)業(yè)化基地。

　　The third one is its great potential for growth. In 2019, the company set a goal of going more globalized by initiating its second-phase construction. Currently, the program to expand production capacity to 3 million pieces of the PEG-rhG-CSF has been accomplished. Two new state first-class drugs, JMT103 and TG103, will be put into production with an estimated 2 billion RMB sales revenue and 200 million RMB taxes added. Following these moves, 7 more new state first-class drugs with an investment of over 2 billion RMB R&D funds will go to market successively, making the new project CSPC’s biggest bio-medicine industry base within China.